

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Tadamitsu Kishimoto <i>et al</i> .)	Group Art Unit: 1615
Application No. 10/785,230)	Examiner: To Be Assigned
Filing Date: February 25, 2004)	
For: Vascularization Inhibitors)	

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. § 1.97(b)</u>

Pursuant to 37 C.F.R. § 1.56 and § 1.97(b), Applicants brings to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the documents were previously submitted to, or cited by, the Office in United States Application No. 09/646,785, filed September 22, 2000 which is relied on for an earlier effective filing date under 35 U.S.C. § 120. Therefore, copies of the documents are not attached. C.F.R. § 1.98(d)

The following documents were also cited in an Information Disclosure Statement in United States Application No. 09/646,785, filed September 22, 2000:

International Search Report (PCT/JP99/01448) dated June 1, 1999; Supplementary Partial European Search Report dated April 15, 2003; and Translation of an International Preliminary Examination Report ("IPER" dated September 2, 1999

Applicants respectfully request that the Examiner consider these three documents.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does

not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b); before the mailing of the first Office action on the merits in the application. No fee is believed to be due for this submission. If the U.S. Patent and Trademark Office deems a fee is due, please charge this fee and any other required fees to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Dated: June 16, 2004 Morgan, Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue Washington, D.C. 20004 202-739-3000 Respectfully submitted,
Morgan, Lewis & Bockius LLP

Suzanne E. Ziska

Registration No. 43,371



ATTY DOCKET NO.	APPLICATION NO		
046124-5042-01-US	10/785,230		
APPLICANTS			
Tadamitsu Kishimoto et al.			
FILING DATE	GROUP		

1615

February 25, 2004

U.S. PATENT DOCUMENTS

	,			· · · · · · · · · · · · · · · · · · ·			
*EXAMINER		į.				-	FILING DATE
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE
	101	5.552.040	10/00/1006	TT!	125	60.1	10/14/1996
	A01	5,563,048	10/08/1996	Honjo et al.	435	69.1	10/14/1990

		FOREIGN PAT	ENT DOCUMENTS				
	OCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B01							_

•	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)				
C01	Arisawa et al., Hepatic Artery Dexamethasone Infusion Inhibits Colorectal Hepatic Metyastases: A Regional Antiangiogenic Therapy, Ann. Surg. Oncol. 2:114-120 (Mar. 1995) Raven Press, Ltd., New York, NY, USA.				
C02	"Dexamethasone - Indications and Usage" (English translation), page C-1712, ISBN4-567-01311-5.				
C03	Feil et al., Endothelial Cells Differentially Express Functional CXC-Chemokine Receptor-4 (CXCR-4/Fusin) Under the Control of Autocrine Activity and Exogenous Cytokines, Biochem. Biophy. Res. Commun. 247:38-45 (Jun. 1998) Academic Press Inc., Orlando, FL, USA.				
C04	Gupta et al., Selective Functional Expression of CXCR4 (Fusin) in Vascular Endothelial Cells and Transcriptional Regulation by Inflammatory Cytokines, FASEB J. 11(9)(suppl.):A1384 (Jul. 1997) Fed. of American Soc. for Experimental Biology, Bethesda, MD, USA.				
C05	Gupta et al., Chemokine Receptors in Human Endothelial Cells, J. Biol. Chem. 273(7):4282-4287 (Feb. 1998) American Society of Biological Chemists, Baltimore, MD, USA.				
C06	Murakami et al., A Small Molecule Inhibitor CXCR4 that Blocks T Cell Line-Tropic HIV-1 Infection, J. Exp. Med. 186(8):1389-1393 (Oct. 1997) Rockefeller University Press, New York, NY, USA.				
C07	Signoret et al., Phorbol Esters and SDF-1 Induce Rapid Endocytosis and Down Modulation of the Chemokine Receptor CXCR4, J. Cell Biol. 193(3):651-664 (Nov. 1997) Rockefeller University Press, New York, NY, USA.				
C08	Suzuki et al., Inhibition of Human Immunodeficiency Virus Type-1 Infection by a Recombinant HIV Vector Expressing Antisense-CXCR4, Blood 92(10)(suppl. 1):386B, (Nov. 1998) W.B. Saunders, Philadelphia, VA, USA.				
C09	Tachibana et al., The Chemokine Receptor CXCR4 is Essential for Vascularization of the Gastrointestinal Tract, <i>Nature</i> 393:591-594 (Jun. 1998) MacMillan Journals Ltd., London, GB.				
C10	Volin et al., Chemokine Receptor CXCR4 Expression in Endothelium, Biochem. Biophys. Res. Commun. 242:46-53 (Jan. 1998) Academic Press Inc., Orlando, FL, USA.				

EXAMINER DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.